Kristie L. Kahl

The time-limited combination of ibrutinib plus chemoimmunotherapy in younger fit patients with chronic lymphocytic leukemia increased the rate of complete responses with bone marrow undetectable minimal residual disease, regardless of IGHV mutation, according to long-term follow-up data.

Among patients with newly diagnosed multiple myeloma, 80% of a study cohort reached MRD negativity following treatment with daratumumab, carfilzomib, lenalidomide, and dexamethasone.

The infusion of E-Coli- and Erwinia-derived asparaginase therapies combined with chemotherapy appeared to be well tolerated with biological efficacy in patients with acute lymphoblastic leukemia under the age of 55, providing an additional option for patients for whom further asparagine treatment is contraindicated due to toxicity.

Data presented at 2021 ASH indicate that 2-year progression-free survival rates were improved when ibrutinib was added to rituximab plus mini-CHOP in an elderly cohort of patients with previously untreated diffuse large B-cell lymphoma.

The combination of daratumumab with bortezomib, cyclophosphamide, and dexamethasone continued to improve hematologic and organ responses after 18 months of follow-up.

Patients with hormone receptor-positive, HER2-negative early breast cancer did not see a benefit when adjuvant palbociclib was added to standard endocrine therapy.

Patients with BCG-unresponsive non-muscle invasive bladder cancer may benefit from treatment with avelumab and BCG induction therapy

Investigators believe the use of biomarkers can determine the results of de-escalated neoadjuvant T-DM1 in HR-positive/HER2-positive early breast cancer.

Treatment with sunitinib resulted in improved efficacy results in the FIRSTMAPPP trial for patients with malignant pheochromocytoma and paraganglioma.

Dr. Christopher Lieu shares his insights into gaps in care in the adjuvant setting in colorectal cancer.

An expert in CRC describes key findings from clinical trials related to personalized detection of molecular recurrence in early stage CRC.

Javier L. Munoz, MD, MS, FACP, discusses how the sequencing of therapies has changed in the last year.

An expert in relapsed/refractory follicular lymphoma discusses the approval of tazemetostat as a treatment and reviews the phase 2 clinical trial data.

Javier L. Munoz, MD, MS, FACP, describes the current third-line treatment options available for relapsed/refractory follicular lymphoma.

Preliminary data from the phase 1b GO30103 study indicated that the combination of tiragolumab plus atezolizumab may have promise in patients with heavily pretreated metastatic esophageal cancer.

Dr. Lee Schwartzberg comments on unmet needs in the treatment of early-stage HR+ [hormone receptor-positive] breast cancer.

Current recommendations for conducting genomic testing in patients with HR+ [hormone receptor-positive] breast cancer, as outlined by the NCCN clinical practice guidelines.

Dr. Lee Schwartzberg highlights recent changes to the NCCN guidelines in terms of guidance for genomic testing in HR-positive breast cancer based on updates to the RxPONDER trial and data supporting the use of the Breast Cancer Index.

Common scenarios for which genomic testing is recommended to aid in treatment decisions for patients with hormone receptor-positive breast cancer.

Lee Schwartzberg, MD, FACP, of West Cancer Center & Research Institute, discusses the role of genomic testing in hormone receptor-positive breast cancer and compares information provided by various assays approved for use.

A specialist explains the factors considered when it comes to choosing treatments for patients with relapsed/refractory follicular lymphoma, and the clinical endpoints to look for.

Javier L. Munoz, MD, MS, FACP, describes the effects of R/R FL and discusses the current treatment options available.

An overview of predictive and prognostic biomarkers used by breast oncologists to aid in adjuvant treatment decisions for HR-positive disease, as outlined by the NCCN guidelines.

The rationale for treating patients with early stage HR-positive breast cancer with extended adjuvant therapy based on lessons learned through clinical trial evidence and real-world practice.

Dr. Daniel Ahn discusses the implications of postoperative ctDNA testing for decision-making in early stage CRC.

At the 18-month follow-up, the CAR T-cell therapy led to early, deep, and durable responses with a manageable safety profile in patients with relapsed/refractory multiple myeloma.

After almost 5 years of follow-up, results strongly support upfront daratumumab with lenalidomide and dexamethasone as a new standard of care for patients with transplant-ineligible newly diagnosed multiple myeloma.

The addition of lenalidomide to rituximab continued to improve survival outcomes with durable responses among patients with indolent B-cell non-Hodgkin lymphomas and mantle cell lymphomas.

Treatment with the off-the-shelf, full-size BCMA X CD3 bi-specific antibody appeared well tolerated with promising efficacy among patients with relapsed/refractory multiple myeloma.

For men with asymptomatic or mildly symptomatic mCRPC, using bone-protecting agents during treatment with radium-223 plus enzalutamide controlled the risk for fractures.